404 related articles for article (PubMed ID: 23274701)
1. The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.
Domingo-Fernandez R; Watters K; Piskareva O; Stallings RL; Bray I
Pediatr Surg Int; 2013 Feb; 29(2):101-19. PubMed ID: 23274701
[TBL] [Abstract][Full Text] [Related]
2. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.
Scaruffi P; Parodi S; Mazzocco K; Defferrari R; Fontana V; Bonassi S; Tonini GP
Mol Diagn; 2004; 8(2):93-100. PubMed ID: 15527323
[TBL] [Abstract][Full Text] [Related]
3. Genetic stratification of neuroblastoma for treatment tailoring.
Jeison M; Yaniv I; Ash S
Future Oncol; 2011 Sep; 7(9):1087-99. PubMed ID: 21919696
[TBL] [Abstract][Full Text] [Related]
4. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
5. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
[TBL] [Abstract][Full Text] [Related]
6. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
7. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
8. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
9. Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Van Roy N; Jauch A; Van Gele M; Laureys G; Versteeg R; De Paepe A; Cremer T; Speleman F
Cancer Genet Cytogenet; 1997 Sep; 97(2):135-42. PubMed ID: 9283597
[TBL] [Abstract][Full Text] [Related]
10. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group.
Lastowska M; Nacheva E; McGuckin A; Curtis A; Grace C; Pearson A; Bown N
Genes Chromosomes Cancer; 1997 Mar; 18(3):162-9. PubMed ID: 9071568
[TBL] [Abstract][Full Text] [Related]
11. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
[TBL] [Abstract][Full Text] [Related]
12. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
13. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
14. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
Wolf M; Korja M; Karhu R; Edgren H; Kilpinen S; Ojala K; Mousses S; Kallioniemi A; Haapasalo H
BMC Cancer; 2010 May; 10():181. PubMed ID: 20444257
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.
Villamón E; Piqueras M; Mackintosh C; Alonso J; de Alava E; Navarro S; Noguera R
Virchows Arch; 2008 Jul; 453(1):47-55. PubMed ID: 18574593
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
Fieuw A; Kumps C; Schramm A; Pattyn F; Menten B; Antonacci F; Sudmant P; Schulte JH; Van Roy N; Vergult S; Buckley PG; De Paepe A; Noguera R; Versteeg R; Stallings R; Eggert A; Vandesompele J; De Preter K; Speleman F
Int J Cancer; 2012 Jun; 130(11):2599-606. PubMed ID: 21796619
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
Scaruffi P; Coco S; Cifuentes F; Albino D; Nair M; Defferrari R; Mazzocco K; Tonini GP
Cancer Genet Cytogenet; 2007 Aug; 177(1):20-9. PubMed ID: 17693187
[TBL] [Abstract][Full Text] [Related]
18. Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Combaret V; Derré J; Couturier J; Aurias A; Delattre O
Cancer Genet Cytogenet; 2003 Feb; 141(1):32-42. PubMed ID: 12581896
[TBL] [Abstract][Full Text] [Related]
19. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
Bray I; Bryan K; Prenter S; Buckley PG; Foley NH; Murphy DM; Alcock L; Mestdagh P; Vandesompele J; Speleman F; London WB; McGrady PW; Higgins DG; O'Meara A; O'Sullivan M; Stallings RL
PLoS One; 2009 Nov; 4(11):e7850. PubMed ID: 19924232
[TBL] [Abstract][Full Text] [Related]
20. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
